OBJECTIVE: Amplatzer (AGA Medical Corporation, Plymouth, Minn) septal and vascular
occluder devices have significantly altered the care of patients with congenital heart …

Objective. To summarize major complications and outcome for patients receiving
percutaneous closure of atrial septal communications. Design. The Medline database and …

The objective of this study was to determine the initial safety and results of unrestricted multi-
institution routine community use of the Amplatzer Septal Occluder (ASO) for atrial septal …

Atrial septal defects (ASD) are among the most common forms of congenital heart disease
accounting for 10% of all defects. Until now, surgical closure was considered the sole …

The objectives of this study were to identify possible risk factors that may lead to erosion of
the Amplatzer septal occluder (ASO) and recommend ways to minimize future risk. There …

Objectives: Results and complications of surgical versus transcatheter treatment of atrial
septal defect in the current era are compared. Methods: All consecutive patients with a …

Use of the Amplatzer Septal Occluder device to close selected secundum atrial septal
defects is ever-increasing. This article illustrates the central role of the echocardiologist …

Our study reports the results of a comparison of closure of atrial septal defect (ASD)
surgically with transcatheter closure using the Amplatzer septal occluder. Patients having an …

Background—Prospective data on the medium-term safety and effectiveness of the
AMPLATZER Septal Occluder in clinical practice are not available. The objective of this …

Objectives: We sought to determine the incidence, nature, and predisposing factors of
atrioventricular block (AVB) associated with closure of atrial septal defects (ASDs) using the …